# The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

> **NCT04818983** · — · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 470 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Extensive Disease Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04818983
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2023-02-03
- **Final completion:** 2023-02-03
- **Target enrollment:** 470 (ACTUAL)
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818983, "The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04818983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*